IFPMA
10.1.2019 10:02:09 CET | Business Wire | Press release
The new Code of Practice of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) came into effect on 1 January 2019. The 2019 Code is marked by two important changes. First, it bans gifts and promotional aids (so-called “goodies”) for prescription medicines, wherever IFPMA member companies operate. Second, it introduces a shift from a rules-based approach to a values-based Code, which seeks to help better guide business behaviors and interactions between IFPMA members and the healthcare community.
Part of the ban on gifts are any exceptions based on the custom of gifts to mark significant national, cultural or religious events (for example, mooncakes or condolence payments). This brings the rest of the world in line with current European and US guidelines. The ban reflects pharma industry’s commitment towards the general concern that the promotional items trivialize the important, professional relationship that must exist between medical representatives and healthcare professionals, and that has the patient’s interests at its core. This relationship is based on the concept that mutual exchange ensures that the patient benefits from all sides sharing expertise and scientific knowledge, enabling the development and effective use of new medicinal products and vaccines.
“We are glad to see that the new pharma industry Code of Practice is value-based, this will lead to the right instinct to put the patient first. From a patient perspective, we support self-regulation for all healthcare professionals and industry. It is important that when they step into a doctor’s cabinet, patients know that they can trust that advice. We are happy to work with the Code and promote it” said Kawaldip Sehmi, CEO of the International Alliance of Patients’ Organizations (IAPO).
Following months of internal preparation to get IFPMA member companies and associations ready for the 2019 Code, the updates were also presented to partners in the Consensus Framework for Ethical Collaboration , including international organizations representing physicians, patients, nurses, and pharmacists (WMA , IAPO , ICN , FIP ).
“Trust is the life-blood of our industry, it is the “north star” for our behaviors. It’s not just what pharmaceutical innovation achieves that matters, but also how the industry goes about achieving it. Implementing the new and revised Code in full is about walking the talk, about earning our license to operate. We encourage doctors, pharmacists, nurses and patients to become aware of the updated ethical standards. The better our stakeholders understand our standards and hold us to account, the easier it will be for us to live-up to our commitments ”, said Thomas Cueni, IFPMA Director-General.
While the 2019 Code still provides rules that drive compliance, IFPMA’s new Ethos aims to go beyond and seeks to instill a culture of ethics and integrity. Trust is at the center of the Ethos and the values of care, fairness, respect and honesty describe how the industry strives to achieve this trust. This new ethical framework will guide business behaviors and interactions between IFPMA members and the healthcare community, no matter how testing the circumstances.
Reflecting the unique role played by the research-based biopharmaceutical industry, the first international self-regulation mechanism in the biopharmaceutical industry was put in place in 1981, called the IFPMA Code of Pharmaceutical Marketing Practice. It preceded even the WHO Ethical Criteria on Medicinal Drug Promotion, which was issued in 1988. Since then, the Code has been revised five times, to ensure that the biopharmaceutical industry remains consistent with society’s changing needs and expectations. With the latest edition of IFPMA Code of Practice, the bar to meet expectations regarding compliance is set even higher.
About IFPMA
IFPMA represents the research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s 2 million employees discover, develop, and deliver medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190110005004/en/
Contact:
IFPMA Morgane De Pol Manager, Communications and Public Affairs m.depol@ifpma.org + 41 22 38 32 00 / +41 79 962 11 95
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From London 1851 to Riyadh 2030: The United Kingdom Continues Its World Expo Legacy with the Signing of Its Participation Contract for Expo 2030 Riyadh19.11.2026 15:10:00 CET | Press release
The United Kingdom has signed its Participation Contract for Expo 2030 Riyadh, confirming its place at one of the world’s largest global gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119617914/en/ The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State for Foreign Affairs, Climate Envoy, and Commissioner General of Expo 2030 Riyadh; and Lord Sarwar, UK Minister for Trade; and Talal Al-Marri, CEO of Expo 2030 Riyadh. The Agreement constitutes a significant milestone in the United Kingdom’s journey towards Expo 2030 Riyadh, establishing the framework for the execution of its pavilion, programming and visitor experience. This latest agreement adds to a growing number of Participation Contract signings, reflecting increasing momentum behind Expo 2030 Riyadh and the value countries are placing on being part of it. The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State
Rimini Street to Host Investor Day on January 14, 2027, in New York City19.11.2026 15:00:00 CET | Press release
The Company will highlight its opportunities and unique solutions in enterprise software support and its ownership of the Agentic AI ERP market, present its sales strategy and financial model and host a panel discussion featuring Rimini Street global clients from a variety of industries Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced details for its upcoming Investor Day, to be held on January 14, 2027, in New York City. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119878624/en/ Rimini Street to Host Investor Day on January 14, 2027, in New York City Investor Day Details Date: January 14, 2027 Time: 8:30 a.m. – 12:30 p.m. Eastern Time Location: New York City In-Person Attendance: Institutional investors and analysts in
Belkin Named CES Innovation Awards® 2027 Honoree for Titan SmartShield Pro Bright Privacy Screen Protector19.11.2026 15:00:00 CET | Press release
Award-winning screen protection technology redefines mobile privacy with a brighter, clearer viewing experience and improved power efficiency Belkin, a leading consumer electronics brand for over 40 years, today announced that its Titan SmartShield Pro Bright Privacy Screen Protector has been named a CES Innovation Awards® 2027 Honoree in the Mobile Devices, Accessories & Apps category. The recognition celebrates Belkin's innovative approach to screen protection, combining enhanced privacy, optical clarity and durability without compromising the everyday smartphone experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119118768/en/ Belkin Named CES Innovation Awards® 2027 Honoree for Titan SmartShield Pro Bright Privacy Screen Protector The CES Innovation Awards® 2027 program received a record number of submissions – nearly 4,000 – ahead of CES 2027, taking place January 6–9 in Las Vegas. The annual competition, owne
Marsh’s Oliver Wyman to Acquire Financial Services and Technology Consultancy Synpulse19.11.2026 14:08:00 CET | Press release
Oliver Wyman, a global leader in management consulting and a Marsh business (NYSE:MRSH), today announced an agreement to acquire Synpulse, a global technology consulting and AI platform company serving banks, insurers, wealth managers and other financial services organizations. Terms of the deal, expected to close in early 2027, were not disclosed. Banks, insurers and asset managers face significant changes driven by advances in technology, data and AI, as well as evolving business models. As these changes accelerate, clients are looking for partners who can help them navigate every stage of transformation, from strategy to technology implementation and execution. Oliver Wyman and Synpulse have already been working together with combined teams on multiple end-to-end transformations for our clients. The acquisition will enable the two businesses to continue to work closely together, combining complementary capabilities and teams to service clients across strategy, technology and impleme
GE HealthCare’s Phase 2 Results Support Advancement of Investigational Manganese-Based MRI Contrast Agent Mangaciclanol Into Phase 3 of LUMINA Clinical Trial19.11.2026 14:00:00 CET | Press release
Key milestone in GE HealthCare’s adaptive Phase 2/3 LUMINA clinical trial, with Phase 2 results meeting primary endpoint, showing mangaciclanol and market-leading gadolinium-based agent, gadobutrol, have similar overall diagnostic preference Mangaciclanol was well tolerated in the Phase 2 stage, with no safety concerns identified following its administration Mangaciclanol has received FDA Fast Track designation, recognizing its potential to address significant unmet patient needs; approximately 65 million gadolinium-enhanced MRI procedures are performed each year GE HealthCare to present preliminary Phase 2 results at RSNA 2026 (Industry Expert Theater) GE HealthCare (Nasdaq: GEHC) today announced Phase 2 results support advancement into Phase 3 for its international, multicenter LUMINA trial of mangaciclanol, with a dose selection of 0.1mmol/kg. Mangaciclanol is an investigational manganese-based magnetic resonance imaging (MRI) contrast agent (MBCA). If approved, MBCAs could offer an
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
